Matthew Doust, MD
Interventional Pain Medicine · Phoenix, AZNPI 1720171143
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 502 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Abbott at 26.7% of the total. Reporting peaked in 2021 at $2,281 and has fallen 94.4% since, to $128 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in AZ, where the typical reported total is $8,993.
Across 502 payments — averaging $12.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Collegium Pharmaceutical, Inc.$870
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$785
- AbbVie$509
- Scilex Pharmaceuticals Inc.$375
- Pfizer$338
- plus $2K from 22 others
Across 899 payments — averaging $13,413 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4.4M
- Modernatx, Inc.$4.2M
- AstraZeneca$1.8M
- Janssen Research & Development, LLC$1.2M
- Bavarian Nordic A/s$195K
- Eli Lilly$150K
- plus $169K from 6 others
What the payments were for
- Food & beverage$6,27599%
- Education$341%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 121 | $1,690 |
| Collegium Pharmaceutical, Inc. | 88 | $870 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 78 | $785 |
| AbbVie | 46 | $509 |
| Scilex Pharmaceuticals Inc. | 31 | $375 |
| Pfizer | 37 | $338 |
| Valinor Pharma, LLC | 27 | $319 |
| Boston Scientific | 9 | $206 |
| Redhill Biopharma Inc. | 13 | $169 |
| Medtronic | 1 | $159 |
| Biodelivery Sciences International, Inc. | 14 | $139 |
| Nevro Corp. | 1 | $137 |
| Nalu Medical, Inc. | 2 | $125 |
| Electronic Waveform Lab, Inc. | 7 | $67 |
| IBSA Pharma Inc. | 3 | $62 |
| Amgen | 4 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Vertiflex, Inc. | 3 | $49 |
| Protega Pharmaceutials Inc | 2 | $39 |
| Tersera Therapeutics LLC | 2 | $32 |
| Daiichi Sankyo Inc. | 2 | $32 |
| GRT US Holding, Inc. | 2 | $26 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Terumo BCT, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| SPR Therapeutics, Inc | 1 | $14 |
| Almatica Pharma LLC | 1 | $12 |
| Radius Health, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,329 in reported general payments places this provider in the 40th percentile of 64 interventional pain medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 20 | $47,056 |
| Xtampza ErOxycodone Myristate | 139 | $42,824 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,070 | $40,479 |
| MovantikNaloxegol Oxalate | 86 | $36,037 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 781 | $22,738 |
| UbrelvyUbrogepant | 12 | $18,692 |
| Oxycodone Hcl | 873 | $12,911 |
| Lidocaine | 128 | $12,448 |
| Morphine Sulfate ErMorphine Sulfate | 401 | $9,326 |
| Gabapentin | 669 | $8,773 |
| Pregabalin | 306 | $5,378 |
| OxycontinOxycodone Hcl | 23 | $5,280 |
| Diclofenac Sodium | 100 | $4,833 |
| Tizanidine Hcl | 282 | $2,779 |
| Hydromorphone Hcl | 103 | $2,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $785 | $47,05620 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $870 | $42,824139 claims |
| Redhill Biopharma Inc.Movantik | $169 | $36,03786 claims |
| AbbVieUbrelvy | $509 | $18,69212 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate | $21 | $2,46167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 64 interventional pain medicine providers in Arizona.
Other interventional pain medicine in Phoenix
- Steven SiwekPhoenix$57K
- Ramoun JonesPhoenix$51K
- Lisa StearnsPhoenix$48K
- Jerome GrovePhoenix$21K
- Thomas MoshiriPhoenix$19K
- Abram BurgherPhoenix$15K
- Adam SiwekPhoenix$14K
- Todd TurleyPhoenix$13K
- Jarrett LeathemPhoenix$11K
- Ankit PatelPhoenix$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.